Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
August 2018—Meridian Life Science released Japanese encephalitis virus pairs suitable for use in ELISAs and immunofluorescence assays. The product is specific for the nonstructural protein 1 (NS1) and exhibits no cross-reactivity with other flaviviruses, including tick-borne encephalitis, yellow fever, West Nile, dengue, Zika, and chikungunya.
August 2018—MilliporeSigma has entered into an agreement with HistoCyte Laboratories (Tyne, U.K.) to be the exclusive multinational distributor of HistoCyte’s cell line reference products for immunohistochemistry and in situ hybridization.
August 2018—Ortho Clinical Diagnostics received the CE mark for the Ortho Vitros XT 7600 integrated chemistry system. The digital chemistry is based on three technologies: dry slide, microslide, and digital imaging. Dry slide technology does not require water to run, which eliminates the risk of poor water quality affecting test results.
August 2018—Agena Bioscience has entered into a commercial partnership agreement with Zhejiang Dian Diagnostics, an independent medical laboratories provider headquartered in Hangzhou, China.
August 2018—Array BioPharma announced that the FDA has approved Braftovi (encorafenib) capsules in combination with Mektovi (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or BRAF V600K mutation, as detected by an FDA-approved test.
August 2018—LGC Maine Standards released its Validate Procalcitonin linearity and calibration verification kit for Abbott Architect analyzers.
August 2018—The FDA has approved Senseonics Holdings’ Eversense Continuous Glucose Monitoring System for adults age 18 and older with diabetes. The system features an implantable glucose sensor and provides long-term continuous monitoring for up to three months.
July 2018—Arlington Scientific announced it has received FDA 510(k) clearance for its ASI Evolution, a fully automated nontreponemal syphilis system for diagnostic testing and blood donor screening.
July 2018—CARB-X has awarded Specific Diagnostics up to $1.7 million to support the development of the company’s antibiotic susceptibility testing system. Up to $1.7 million more could be awarded based on achievement of project milestones. Specific’s AST instrument determines phenotypic antibiotic susceptibility within hours of blood infection.
July 2018—Cancer Genetics announced it has received special 510(k) clearance from the FDA for its Tissue of Origin test following modifications made to test reagents and software.
